Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of ($0.29), $0.08 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $212.5 million versus the consensus estimate of $192.9 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.